Oruka Therapeutics, Inc.
ORKA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000907654
In the last 90 days, Oruka Therapeutics, Inc. insiders filed 0 open-market purchases and 15 sales; 255 institutions reported holding it in 13F filings for Q2 2026, worth $7.05B in total; Viking Global Investors is the only superinvestor holding it.
Q1 2025 vs. Q4 2024
How the institutions holding Oruka Therapeutics, Inc. changed between Q4 2024 and Q1 2025.
All holders in Q1 2025All holders in Q4 2024
| Measure | Q4 2024 | Of which not filed for Q1 2025 | Q1 2025 | Change |
|---|---|---|---|---|
| Holders | 66 | 1 | 71 | +6 |
| Shares | 31.0M | 6.14K | 31.8M | +744.4K (+2.4%) |
| Value | $606.6M | $119.1K | $326.1M | −$280.4M (−46.2%) |
1 institution that held it in Q4 2024 haven't filed for Q1 2025 yet. Not filing isn't selling, so the changes leave them out.
New holders (16)
Institutions that held Oruka Therapeutics, Inc. at the end of Q1 2025 but not at the end of Q4 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Susquehanna International Group, LLP | 350,036 | $3.59M | 0.01% |
| Goldman Sachs Group Inc | 244,199 | $2.51M | 0.00% |
| Ikarian Capital, LLC | 175,000 | $1.80M | 0.58% |
| ADAR1 Capital Management, LLC | 132,780 | $1.36M | 0.26% |
| Candriam Luxembourg S.C.A. | 116,698 | $1.20M | 0.01% |
| Boothbay Fund Management, LLC | 53,615 | $550.1K | 0.02% |
| HRT Financial LP | 46,511 | $477.0K | 0.00% |
| ExodusPoint Capital Management, LP | 35,912 | $368.0K | 0.00% |
| Renaissance Technologies LLC | 35,800 | $367.3K | 0.00% |
| Occudo Quantitative Strategies LP | 24,804 | $310.1K | 0.04% |
| Man Group plc | 29,365 | $301.3K | 0.00% |
| Two Sigma Investments, LP | 21,831 | $224.0K | 0.00% |
| Cannon Global Investment Management, LLC | 19,000 | $194.9K | 0.54% |
| Quest Partners LLC | 16,335 | $167.6K | 0.02% |
| Artia Global Partners LP | 7,380 | $75.7K | 0.02% |
| Coldstream Capital Management Inc | 180 | $1.85K | 0.00% |
Sold out (10)
Institutions that held Oruka Therapeutics, Inc. at the end of Q4 2024 and filed for Q1 2025 without it.
| Institution | Shares, Q4 2024 | Value, Q4 2024 |
|---|---|---|
| Janus Henderson Group PLC | 849,410 | $16.4M |
| Perceptive Advisors LLC | 845,567 | $16.4M |
| Paradigm Biocapital Advisors LP | 819,660 | $15.9M |
| Driehaus Capital Management LLC | 308,795 | $5.99M |
| Great Point Partners LLC | 228,803 | $4.44M |
| Adage Capital Partners GP, L.L.C. | 69,200 | $1.34M |
| 683 Capital Management, LLC | 33,875 | $656.8K |
| Ensign Peak Advisors, Inc | 25,000 | $484.8K |
| Jane Street Group, LLC | 17,706 | $343.3K |
| Aster Capital Management (DIFC) Ltd | 5 | $97 |
Not filed for Q1 2025 yet (1)
Institutions that held Oruka Therapeutics, Inc. at the end of Q4 2024 and haven't filed a 13F for Q1 2025. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2024 | Value, Q4 2024 |
|---|---|---|
| AlphaCentric Advisors LLC | 6,140 | $119.1K |